Abstract
Background Atopic dermatitis (AD) is the most common form of eczema. As leukotriene mediators are involved in the inflammatory phase of atopic dermatitis, montelukast has been suggested as a possible therapy. Aim of the review To evaluate the safety and efficacy of montelukast off-label use for the treatment atopic dermatitis. Method A search was performed from database inception until March 2018 in six electronic databases for randomized-controlled-trials examining the use of montelukast for AD. Results Among 301 articles screened, 11 studies met the inclusion criteria and were included in the review. The study populations consist of paediatric and adult subjects with moderate-to-severe AD. Montelukast use was shown to improve symptoms such as pruritus in four studies. Another 2 studies reported that montelukast could improve symptoms similar to the standard regimen of topical steroid and oral antihistamine. However, five studies reported that montelukast had no effects in symptoms alleviation. The use of montelukast was associated with a similar safety profile to placebo and well-tolerated with minimal adverse effects. Conclusion There is limited evidence to suggest that the off-label use of montelukast is effective in treating moderate-to-severe AD. Further research with larger study populations employing standardized endpoint measuring instrument is warranted to further investigate the off-label use of montelukast in AD treatment. Until then, the use of conventional treatments including optimal daily skin hydration should remain the mainstay in the management of atopic dermatitis. In fact, for moderate-to-severe condition, steroid sparing immune-suppressants should still be used clinically until more effective and safer alternative is discovered.
Similar content being viewed by others
Abbreviations
- AD:
-
Atopic dermatitis
- RCTs:
-
Randomized rontrolled trials
- LTRA:
-
Cysteinyl-leukotriene-1 receptor antagonist
- IgE:
-
Immunoglobulin E
- LTs:
-
Leukotrienes
- SCORAD:
-
Severity Scoring of Atopic Dermatitis
- SASSAD:
-
Six Area, Six Sign Atopic Dermatitis
- EASI:
-
Eczema Area and Severity Index
- ADASI:
-
Atopic Dermatitis Area and Severity Index
- IGA:
-
Investigators’ Global Assessment
- LTE4:
-
Leukotriene E4
- EDN/EPX:
-
Eosinophil-derived neurotoxin/eosinophilic protein X
- ECP:
-
Eosinophilic cationic protein
- QoL:
-
Quality of life
- CDLQI:
-
Children’s Dermatology Life Quality Index
- CBC:
-
Complete blood count
References
Kagi MK. Leukotriene receptor antagonists—a novel therapeutic approach in atopic dermatitis? Dermatology. 2001;203(4):280–3.
Rackal J, Vender R. The treatment of atopic dermatitis and other dermatoses with leukotriene antagonists. Skin Therapy Lett. 2004;9(2):1–5.
Nettis E, D’Erasmo M, Di Leo E, Calogiuri G, Montinaro V, Ferrannini A, et al. The employment of leukotriene antagonists in cutaneous diseases belonging to allergological field. Mediat Inflamm. 2010; 2010 (no pagination) (628171).
Saeki H, Furue M, Furukawa F, Hide M, Ohtsuki M, Katayama I, et al. Guidelines for management of atopic dermatitis. J Dermatol. 2009;36(10):563–77. https://doi.org/10.1111/j.1346-8138.2009.00706.x.
Lee AY. Is montelukast benefical in children with atopic dermatitis? Allergy Asthma Immunol Res. 2016;8(4):279–81.
Leung DYM. Pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 1999;104(3):99–108. https://doi.org/10.1016/s0091-6749(99)70051-5.
Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014;69(1):3–16. https://doi.org/10.1111/all.12270.
Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8–16. https://doi.org/10.1159/000370220.
Harrop J, Chinn S, Verlato G, Olivieri M, Norback D, Wjst M, et al. Eczema, atopy and allergen exposure in adults: a population-based study. Clin Exp Allergy. 2007;37(4):526–35. https://doi.org/10.1111/j.1365-2222.2007.02679.x.
Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60(8):984–92. https://doi.org/10.1111/j.1742-1241.2006.01047.x.
Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014;133(2):429–38. https://doi.org/10.1016/j.jaci.2013.07.049.
Boguniewicz M. Biologic therapy for atopic dermatitis: moving beyond the practice parameter and guidelines. J Allergy Clin Immunol Pract. 2017;5(6):1477–87. https://doi.org/10.1016/j.jaip.2017.08.031.
Brar K, Leung DYM. Recent considerations in the use of recombinant interferon gamma for biological therapy of atopic dermatitis. Expert Opin Biol Therapy. 2016;16(4):507–14. https://doi.org/10.1517/14712598.2016.1135898.
Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: part 3: management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–49. https://doi.org/10.1016/j.jaad.2014.03.030.
Wedi B, Kapp A. Pathophysiological role of leukotrienes in dermatological diseases: potential therapeutic implications. BioDrugs. 2001;15(11):729–43.
Capra V, Ambrosio M, Riccioni G, Rovati GE. Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities. Curr Med Chem. 2006;13(26):3213–26.
Brain SD, Williams TJ. Leukotrienes and inflammation. Pharmacol Ther. 1990;46(1):57–66. https://doi.org/10.1016/0163-7258(90)90035-Z.
Fuller RW, Black PN, Dollery CT. Effect of the oral leukotriene D4 antagonist LY171883 on inhaled and intradermal challenge with antigen and leukotriene D4 in atopic subjects. J Allergy Clin Immunol. 1989;83(5):939–44.
Talbot SF, Atkins PC, Goetzl EJ, Zweiman B. Accumulation of leukotriene C4 and histamine in human allergic skin reactions. J Clin Investig. 1985;76(2):650–6. https://doi.org/10.1172/jci112018.
James JM, Kagey-Sobotka A, Sampson HA. Patients with severe atopic dermatitis have activated circulating basophils. J Allergy Clin Immunol. 1993;91(6):1155–62.
Adamek-Guzik T, Guzik TJ, Czerniawska-Mysik G, Korpanty G, Mastalerz L, Radwan J, et al. Urinary leukotriene levels are increased during exacerbation of atopic eczema/dermatitis syndrome. Relation to clinical status. Allergy. 2002;57(8):732–6.
Riccioni G, Bucciarelli T, Mancini B, Di Ilio C, D’Orazio N. Antileukotriene drugs: clinical application, effectiveness and safety. Curr Med Chem. 2007;14(18):1966–77.
De Lepeleire I, Reiss TF, Rochette F, Botto A, Zhang J, Kundu S, et al. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther. 1997;61(1):83–92. https://doi.org/10.1016/s0009-9236(97)90184-3.
Philip G, Malmstrom K, Hampel FC, Weinstein SF, LaForce CF, Ratner PH, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy. 2002;32(7):1020–8.
Sansom JE, Taylor GW, Dollery CT, Archer CB. Urinary leukotriene E4 levels in patients with atopic dermatitis. Br J Dermatol. 1997;136(5):790–1.
Hishinuma T, Suzuki N, Aiba S, Tagami H, Mizugaki M. Increased urinary leukotriene E4 excretion in patients with atopic dermatitis. Br J Dermatol. 2001;144(1):19–23.
Hon KL, Leung TF, Ma KC, Li AM, Wong Y, Li CY, et al. Urinary leukotriene E4 correlates with severity of atopic dermatitis in children. Clin Exp Dermatol. 2004;29(3):277–81. https://doi.org/10.1111/j.1365-2230.2004.01512.x.
Biswas P, Wilton LV, Shakir SA. Montelukast and improvement of eczema: observations from a prescription event monitoring study in England. Int J Clin Pharmacol Ther. 2001;39(12):529–33.
Broshtilova V, Gantcheva M. Therapeutic hotline: cysteinyl leukotriene receptor antagonist montelukast in the treatment of atopic dermatitis. Dermatol Ther. 2010;23(1):90–3. https://doi.org/10.1111/j.1529-8019.2009.01295.x.
Hon KL, Leung TF, Ma KC, Wong Y, Fok TF. Brief case series: montelukast, at doses recommended for asthma treatment, reduces disease severity and increases soluble CD14 in children with atopic dermatitis. J Dermatol Treat. 2005;16(1):15–8. https://doi.org/10.1080/09546630510026328.
Silverberg NB, Paller AS. Leukotriene receptor antagonists are ineffective for severe atopic dermatitis [8]. J Am Acad Dermatol. 2004;50(3):485–6.
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928.
Jeon YH, Min TK, Yang HJ, Pyun BY. A double-blind, randomized, crossover study to compare the effectiveness of montelukast on atopic dermatitis in Korean children. Allergy Asthma Immunol Res. 2016;8(4):305–11.
Ehlayel MS, Bener A. Does montelukast reduce the treatment cost in children with moderately severe atopic dermatitis. Curr Pediatr Res. 2008;12(1–2):1–4.
Pei AY, Chan HH, Leung TF. Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study. Pediatr Allergy Immunol. 2001;12(3):154–8.
Melamed IR, Robinson L, Heffron M. The benefit of montelukast in atopic dermatitis induced by food allergies. J Allergy Clin Immunol. 2017;125(2):AB93. https://doi.org/10.1016/j.jaci.2009.12.366.
Yanase DJ, David-Bajar K. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol. 2001;44(1):89–93.
Lehtimaki L, Petays T, Haahtela T. Montelukast is not effective in controlling allergic symptoms outside the airways: a randomised double-blind placebo-controlled crossover study. Int Arch Allergy Immunol. 2009;149(2):150–3.
Eustachio N, Alessandro P, Margherita F, Antonio F, Tursi A. Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults [1]. Acta Dermato-Venereol. 2002;82(4):297–8.
Capella GL, Frigerio E, Altomare G. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. Eur J Dermatol. 2001;11(3):209–13.
Friedmann PS, Palmer R, Tan E, Ogboli M, Barclay G, Hotchkiss K, et al. A double-blind, placebo-controlled trial of montelukast in adult atopic eczema. Clin Exp Allergy. 2007;37(10):1536–40.
Rahman ML, Choudhury AM, Islam MM. Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Med J (MMJ). 2006;15(1):85–8.
Veien NK, Busch-Sorensen M, Stausbol-Gron B. Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2005;53(1):147–9.
Chalmers JR, Schmitt J, Apfelbacher C, Dohil M, Eichenfield LF, Simpson EL, et al. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). Br J Dermatol. 2014;171(6):1318–25. https://doi.org/10.1111/bjd.13237.
Storms W, Michele T, Knorr B, Noonan G, Shapiro G, Zhang J, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged ≥ 6 years. Clin Exp Allergy. 2001;31(1):77–87.
Garritsen FM, Roekevisch E, van der Schaft J, Deinum J, Spuls PI, de Bruin-Weller MS. Ten years experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centres. J Eur Acad Dermatol Venereol (JEADV). 2015;29(10):1905–12. https://doi.org/10.1111/jdv.13064.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
Both authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Chin, W.K., Lee, S.W.H. A systematic review on the off-label use of montelukast in atopic dermatitis treatment. Int J Clin Pharm 40, 963–976 (2018). https://doi.org/10.1007/s11096-018-0655-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-018-0655-3